Y Sun1, Q Duan1, X Chen1, W Chen1, X Jin1, R Wu2. 1. Department of Medical Oncology, Shengjing Hospital of China Medical University, 39 Huaxiang Road, Shenyang, 110022, People's Republic of China. 2. Department of Medical Oncology, Shengjing Hospital of China Medical University, 39 Huaxiang Road, Shenyang, 110022, People's Republic of China. 13709858148@163.com.
Abstract
PURPOSE: We compared the clinical efficacy and toxicity of stereotactic body radiotherapy with induction chemotherapy and concurrent radiochemotherapy vs stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma. METHODS: We retrospectively analyzed 38 patients with c-stage T1-3N0M0 non-small cell lung carcinoma who received stereotactic body radiotherapy. All patients received six cycles of chemotherapy. Fifteen of the patients were treated with three cycles of induction chemotherapy, one cycle of concurrent radiochemotherapy, and then two cycles of consolidation chemotherapy, while 23 patients received Sequential Radiotherapy/Chemotherapy. RESULTS: Patients in the induction chemotherapy group experienced a longer duration of esophagitis (median 2 vs 0, range 0-6 vs 0-3.6 weeks, p = 0.04). We divided the patients into two groups based on their median pre-treatment tumor volume (cm3): >32.11 and ≤32.11. The tumor response rate in patients with larger tumor volume was substantially higher in the induction chemotherapy group than in the Sequential Radiotherapy/Chemotherapy group (66.67 vs 40%). Among patients with pre-treatment tumor volume (cm3) >32.11, the median local progression-free survival (LPFS) in the induction chemotherapy group and Sequential Radiotherapy/Chemotherapy group was 18 months (range 7-72 months) and 11 months (range 6-53 months), respectively. There was a statistically significant difference between the two groups (p = 0.006). CONCLUSIONS: Simultaneous SBRT and chemotherapy can result in a longer duration of esophagitis. However, for patients with large tumor volume, ICT combined with concurrent radiochemotherapy may result in better local tumor response as well as longer LPFS and progression-free survival. To better elucidate the best treatment, further clinical trials are needed.
PURPOSE: We compared the clinical efficacy and toxicity of stereotactic body radiotherapy with induction chemotherapy and concurrent radiochemotherapy vs stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma. METHODS: We retrospectively analyzed 38 patients with c-stage T1-3N0M0 non-small cell lung carcinoma who received stereotactic body radiotherapy. All patients received six cycles of chemotherapy. Fifteen of the patients were treated with three cycles of induction chemotherapy, one cycle of concurrent radiochemotherapy, and then two cycles of consolidation chemotherapy, while 23 patients received Sequential Radiotherapy/Chemotherapy. RESULTS:Patients in the induction chemotherapy group experienced a longer duration of esophagitis (median 2 vs 0, range 0-6 vs 0-3.6 weeks, p = 0.04). We divided the patients into two groups based on their median pre-treatment tumor volume (cm3): >32.11 and ≤32.11. The tumor response rate in patients with larger tumor volume was substantially higher in the induction chemotherapy group than in the Sequential Radiotherapy/Chemotherapy group (66.67 vs 40%). Among patients with pre-treatment tumor volume (cm3) >32.11, the median local progression-free survival (LPFS) in the induction chemotherapy group and Sequential Radiotherapy/Chemotherapy group was 18 months (range 7-72 months) and 11 months (range 6-53 months), respectively. There was a statistically significant difference between the two groups (p = 0.006). CONCLUSIONS: Simultaneous SBRT and chemotherapy can result in a longer duration of esophagitis. However, for patients with large tumor volume, ICT combined with concurrent radiochemotherapy may result in better local tumor response as well as longer LPFS and progression-free survival. To better elucidate the best treatment, further clinical trials are needed.
Authors: Vivek Verma; Valerie K Shostrom; Sameera S Kumar; Weining Zhen; Christopher L Hallemeier; Steve E Braunstein; John Holland; Matthew M Harkenrider; Adrian S Iskhanian; Hanmanth J Neboori; Salma K Jabbour; Albert Attia; Percy Lee; Fiori Alite; Joshua M Walker; John M Stahl; Kyle Wang; Brian S Bingham; Christina Hadzitheodorou; Roy H Decker; Ronald C McGarry; Charles B Simone Journal: Cancer Date: 2016-10-14 Impact factor: 6.860
Authors: Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Guy C Jones; Jason D Kehrer; Jenna Kahn; Bobby N Koneru; Ram Narayan; Tarita O Thomas; Kevin Camphausen; Minesh P Mehta; Aradhana Kaushal Journal: Clin Lung Cancer Date: 2015-04-23 Impact factor: 4.785
Authors: Kylie H Kang; Christian C Okoye; Ravi B Patel; Shankar Siva; Tithi Biswas; Rodney J Ellis; Min Yao; Mitchell Machtay; Simon S Lo Journal: Cancers (Basel) Date: 2015-06-15 Impact factor: 6.639